<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289391</url>
  </required_header>
  <id_info>
    <org_study_id>Dexmedetomidine-14115</org_study_id>
    <nct_id>NCT02289391</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia</brief_title>
  <official_title>Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia-single Center,Randomized,Double-blind，Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study try to illustrate the possible mechanisms of tending to induce airway spasms and
      the impact of dexmedetomidine on inflammatory reaction in general anesthesia patients with
      asthma，by detecting the differences of plasma inflammatory factor interleukin(IL)-4, IL-5,
      IL-13, IL-17, IL-33, MBP and immunoglobulin E(IgE) levels between asthma patients and
      non-asthma patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL-4，IL-5，IL-13, IL-17, IL-33 concentration in the Plasma</measure>
    <time_frame>enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Histamine concentration</measure>
    <time_frame>enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myelin Basic Protein concentration （MBP)</measure>
    <time_frame>enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>IgE concentration</measure>
    <time_frame>enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure（MAP）</measure>
    <time_frame>enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate（HR）</measure>
    <time_frame>enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate（RR）</measure>
    <time_frame>enter the operation room(T0)、10min after intubation(T1)、 skin incision(T2)、the end of surgery(T3)、24H after surgery(T4)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anesthesia</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>non-asthma group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-asthma history
Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.
Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.
Stop infusion of normal saline at 10 minutes before the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a history of asthma
Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.
Infusion of dexmedetomidine at 0.4μg•kg-1•h-1during anesthesia maintenance.
Stop infusion of dexmedetomidine at 10 minutes before the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a history of asthma
Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.
Infusion of dexmedetomidine at 0.7μg•kg-1•h-1during anesthesia maintenance.
Stop infusion of dexmedetomidine at 10 minutes before the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>With a history of asthma
Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.
Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.
Stop infusion of normal saline at 10 minutes before the end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anesthesia induction</intervention_name>
    <description>-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.</description>
    <arm_group_label>non-asthma group</arm_group_label>
    <arm_group_label>Dexmedetomidine A</arm_group_label>
    <arm_group_label>Dexmedetomidine B</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anesthesia maintenance</intervention_name>
    <description>Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3~8mg/(kg•h).
Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30~40 mmHg and bispectral index (BIS) to 45~60.</description>
    <arm_group_label>non-asthma group</arm_group_label>
    <arm_group_label>Dexmedetomidine A</arm_group_label>
    <arm_group_label>Dexmedetomidine B</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Assisted anesthesia</intervention_name>
    <description>Intervention 'Assisted anesthesia' has been included in Arm Descriptions.</description>
    <arm_group_label>Dexmedetomidine A</arm_group_label>
    <arm_group_label>Dexmedetomidine B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obtain informed consent

          -  Elective general anesthesia surgery, surgery time 1 ~ 3 hours.

          -  20 patients with a history of asthma.

          -  60 patients with no history of asthma.

          -  American Society of Anesthesiologists (ASA)classification:class I~II.

          -  Aged between 18 and 65 years old.

        Exclusion Criteria:

          -  SBP≥180 mmHg or &lt;90 mmHg, DBP≥110 mmHg or &lt;60 mmHg.

          -  Serious heart, brain, liver, kidney, lung, endocrine diseases or serious infections.

          -  Hematopoietic dysfunction or bleeding tendency and hemorrhagic disease.

          -  A neuromuscular system disease.

          -  Airway and lung surgery.

          -  Predict possible or happened difficult airway.

          -  Immune function defect.

          -  Sure/suspected abuse of narcotic analgesics or drugs or alcohol dependence.

          -  The test drug allergy or have other contraindications in patients.

          -  Childbearing age women not to take appropriate contraception, pregnancy or lactation.

          -  Participated in other clinical drug research in the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NIU XIAOLI</last_name>
    <role>Principal Investigator</role>
    <affiliation>The second affiliated hospital of xi 'an jiaotong university</affiliation>
  </overall_official>
  <reference>
    <citation>Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008 Nov;118(11):3546-56. doi: 10.1172/JCI36130. Review.</citation>
    <PMID>18982161</PMID>
  </reference>
  <reference>
    <citation>Saito A, Okazaki H, Sugawara I, Yamamoto K, Takizawa H. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol. 2003 Oct;132(2):168-76.</citation>
    <PMID>14600429</PMID>
  </reference>
  <reference>
    <citation>Wen FQ, Kohyama T, Liu X, Zhu YK, Wang H, Kim HJ, Kobayashi T, Abe S, Spurzem JR, Rennard SI. Interleukin-4- and interleukin-13-enhanced transforming growth factor-beta2 production in cultured human bronchial epithelial cells is attenuated by interferon-gamma. Am J Respir Cell Mol Biol. 2002 Apr;26(4):484-90.</citation>
    <PMID>11919085</PMID>
  </reference>
  <reference>
    <citation>Laporte JC, Moore PE, Baraldo S, Jouvin MH, Church TL, Schwartzman IN, Panettieri RA Jr, Kinet JP, Shore SA. Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am J Respir Crit Care Med. 2001 Jul 1;164(1):141-8.</citation>
    <PMID>11435252</PMID>
  </reference>
  <reference>
    <citation>Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004 Jun;32(6):1322-6.</citation>
    <PMID>15187514</PMID>
  </reference>
  <reference>
    <citation>Kumar RK, Herbert C, Yang M, Koskinen AM, McKenzie AN, Foster PS. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy. 2002 Jul;32(7):1104-11.</citation>
    <PMID>12100061</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>November 10, 2014</last_update_submitted>
  <last_update_submitted_qc>November 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Inflammatory factor</keyword>
  <keyword>Inflammatory mediator</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

